Transition from Any Other Long‑Acting Injectable (LAI) Antipsychotic to INVEGA SUSTENNA® to INVEGA TRINZA®
| Dose Information |
|---|
Graph Information
Transition to INVEGA TRINZA® from Any Other LAI Antipsychotic (Any Other LAI Antipsychotic to INVEGA SUSTENNA® to INVEGA TRINZA®)
Consistent with the INVEGA TRINZA® Prescribing Information:
- Clinically stable patients entering the INVEGA TRINZA® long-term maintenance study who were being treated with a long-acting injectable antipsychotic product (other than RISPERDAL CONSTA®) were transitioned to 234 mg of INVEGA SUSTENNA® administered in the deltoid muscle in place of the next scheduled injection.
- INVEGA TRINZA® is to be used only after INVEGA SUSTENNA® has been established as adequate treatment for at least four months. Adjust the INVEGA SUSTENNA® dose (78 mg, 117 mg, 156 mg, or 234 mg) according to efficacy/tolerability needs of the patient. Conversion from the INVEGA SUSTENNA® 39 mg dose was not studied.
- In order to establish a consistent maintenance dose, it is recommended that the last two doses of INVEGA SUSTENNA® be the same dosage strength before starting INVEGA TRINZA®.
- Initiate INVEGA TRINZA® when the next INVEGA SUSTENNA® is scheduled with an INVEGA TRINZA® dose based on the previous INVEGA SUSTENNA® dose, using the equivalent 3.5-fold higher dose as shown in table below.
INVEGA TRINZA® Doses for Adult Patients Adequately Treated with INVEGA SUSTENNA®
|
If the Last Dose of INVEGA SUSTENNA® is: |
Initiate INVEGA TRINZA® at the Following Dose: |
|
78 mg |
273 mg |
|
117 mg |
410 mg |
|
156 mg |
546 mg |
|
234 mg |
819 mg |
Conversion from the INVEGA SUSTENNA® 39 mg dose was not studied.
- INVEGA TRINZA® should be administered every 3 months.
- If needed, dose adjustment can be made every 3 months in increments within the range of 273 mg to 819 mg based on individual patient tolerability and/or efficacy. Due to the long-acting nature of INVEGA TRINZA®, the patient’s response to an adjusted dose may not be apparent for several months.
- In a long-term placebo-controlled randomized-withdrawal trial, the percentages of patients with schizophrenia entering the double-blind phase on each of the INVEGA TRINZA® dosage strengths were 4% for 273 mg, 9% for 410 mg, 49% for 546 mg, and 38% for 819 mg.
- Since other LAI antipsychotics (other than RISPERDAL CONSTA®) are not related to the paliperidone compound, the cumulative plasma level curve will not reflect the plasma level contributions from the previous LAI antipsychotic treatment in this scenario.
- Administration: For intramuscular injection only by a healthcare professional. Care should be taken to avoid inadvertent injection into a blood vessel.
INVEGA TRINZA® Prescribing Information [http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INVEGA+TRINZA-pi.pdf]
INVEGA SUSTENNA® Prescribing Information [http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INVEGA+SUSTENNA-pi.pdf]